Unparalleled gene therapy and rare disease expertise

Incorporated in August 2021 and launched in October 2022, we are a spin-out from University College London (UCL), emerging from the world-leading gene therapy and rare diseases expertise of our academic founders, Prof Paul Gissen, Prof Manju Kurian, Prof Ahad Rahim and Prof Simon Waddington. Our £5 million Seed funding round was led by UCL Technology Fund, which is managed by AlbionVC, one of the largest independent venture capital investors in the UK, in collaboration with UCL Business.